FI3921033T3 - Arginaasiestäjiä ja menetelmiä niiden käyttämiseksi - Google Patents

Arginaasiestäjiä ja menetelmiä niiden käyttämiseksi Download PDF

Info

Publication number
FI3921033T3
FI3921033T3 FIEP20709706.4T FI20709706T FI3921033T3 FI 3921033 T3 FI3921033 T3 FI 3921033T3 FI 20709706 T FI20709706 T FI 20709706T FI 3921033 T3 FI3921033 T3 FI 3921033T3
Authority
FI
Finland
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
formula
alkyl
Prior art date
Application number
FIEP20709706.4T
Other languages
English (en)
Finnish (fi)
Inventor
Scott Nathan Mlynarski
Tyler Grebe
Sameer Kawatkar
Maurice Raymond Verschoyle Finlay
Iain Simpson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of FI3921033T3 publication Critical patent/FI3921033T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FIEP20709706.4T 2019-02-08 2020-02-07 Arginaasiestäjiä ja menetelmiä niiden käyttämiseksi FI3921033T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962802765P 2019-02-08 2019-02-08
PCT/IB2020/050982 WO2020161675A1 (en) 2019-02-08 2020-02-07 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
FI3921033T3 true FI3921033T3 (fi) 2023-09-15

Family

ID=69770954

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20709706.4T FI3921033T3 (fi) 2019-02-08 2020-02-07 Arginaasiestäjiä ja menetelmiä niiden käyttämiseksi

Country Status (32)

Country Link
US (2) US12435097B2 (cg-RX-API-DMAC7.html)
EP (1) EP3921033B1 (cg-RX-API-DMAC7.html)
JP (1) JP7526734B2 (cg-RX-API-DMAC7.html)
KR (1) KR102759971B1 (cg-RX-API-DMAC7.html)
CN (1) CN113395996B (cg-RX-API-DMAC7.html)
AU (1) AU2020218651B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021015581A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021002056A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021011039A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210463A (cg-RX-API-DMAC7.html)
DK (1) DK3921033T3 (cg-RX-API-DMAC7.html)
DO (2) DOP2021000166A (cg-RX-API-DMAC7.html)
EA (1) EA202192114A1 (cg-RX-API-DMAC7.html)
ES (1) ES2960034T3 (cg-RX-API-DMAC7.html)
FI (1) FI3921033T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231092T1 (cg-RX-API-DMAC7.html)
HU (1) HUE062968T2 (cg-RX-API-DMAC7.html)
IL (1) IL285108B2 (cg-RX-API-DMAC7.html)
LT (1) LT3921033T (cg-RX-API-DMAC7.html)
MA (1) MA56324B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021009499A (cg-RX-API-DMAC7.html)
MY (1) MY206577A (cg-RX-API-DMAC7.html)
PE (1) PE20220280A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551902A1 (cg-RX-API-DMAC7.html)
PL (1) PL3921033T3 (cg-RX-API-DMAC7.html)
PT (1) PT3921033T (cg-RX-API-DMAC7.html)
RS (1) RS64781B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108503PA (cg-RX-API-DMAC7.html)
SI (1) SI3921033T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300337T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020161675A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202105833B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007739XA (en) * 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
SE0300907D0 (sv) * 2003-03-31 2003-03-31 Astrazeneca Ab Novel compounds
WO2010085797A2 (en) 2009-01-26 2010-07-29 The Trustees Of University Of Pennsylvania Arginase inhibitors and methods of use
EP2560978B1 (en) * 2010-04-22 2019-01-30 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
EP3034509B1 (en) * 2010-10-26 2020-04-22 Mars, Incorporated Arginase inhibitors as therapeutics
CA2852685C (en) 2011-10-19 2019-02-26 Mars, Incorporated Inhibitors of arginase and their therapeutic application
RU2671976C2 (ru) 2012-12-17 2018-11-08 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
PL410665A1 (pl) * 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2016281620B2 (en) * 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2017175185A1 (en) * 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
WO2018119440A1 (en) * 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CN108794517B (zh) * 2017-04-27 2021-03-30 南京谷睿生物科技有限公司 一种精氨酸酶抑制剂及其制备方法与用途
SG11202007739XA (en) * 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
US12215116B2 (en) * 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2019205979A1 (zh) * 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
MA53427B1 (fr) 2018-08-22 2024-06-28 Astrazeneca Ab Inhibiteurs de l'arginase et leurs méthodes d'utilisation

Also Published As

Publication number Publication date
DK3921033T3 (da) 2023-10-16
AU2020218651B2 (en) 2023-01-12
MY206577A (en) 2024-12-24
JP2022521474A (ja) 2022-04-08
KR102759971B1 (ko) 2025-01-23
DOP2021000166A (es) 2021-09-30
HRP20231092T1 (hr) 2023-12-22
IL285108B1 (en) 2024-06-01
IL285108A (en) 2021-09-30
MX2021009499A (es) 2021-09-08
KR20210126044A (ko) 2021-10-19
PL3921033T3 (pl) 2024-01-15
BR112021015581A2 (pt) 2021-10-05
HUE062968T2 (hu) 2023-12-28
CL2021002056A1 (es) 2022-03-04
ZA202105833B (en) 2025-03-26
ES2960034T3 (es) 2024-02-29
PE20220280A1 (es) 2022-02-25
CR20210463A (es) 2021-10-15
IL285108B2 (en) 2024-10-01
WO2020161675A1 (en) 2020-08-13
CN113395996A (zh) 2021-09-14
US20220106335A1 (en) 2022-04-07
RS64781B1 (sr) 2023-11-30
EA202192114A1 (ru) 2021-12-01
SG11202108503PA (en) 2021-09-29
EP3921033B1 (en) 2023-07-26
JP7526734B2 (ja) 2024-08-01
US12435097B2 (en) 2025-10-07
CA3127755A1 (en) 2020-08-13
PH12021551902A1 (en) 2022-08-01
SMT202300337T1 (it) 2023-11-13
CN113395996B (zh) 2024-05-28
EP3921033A1 (en) 2021-12-15
SI3921033T1 (sl) 2023-11-30
LT3921033T (lt) 2023-09-25
CO2021011039A2 (es) 2021-09-09
AU2020218651A1 (en) 2021-09-30
US20250282800A1 (en) 2025-09-11
MA56324B1 (fr) 2023-10-31
DOP2024000181A (es) 2024-10-15
PT3921033T (pt) 2023-10-11

Similar Documents

Publication Publication Date Title
HRP20201984T1 (hr) Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
CR20200418A (es) Inhibidores de orginasa y sus mètodos de uso antecedentes
HRP20171189T1 (hr) Bisaril-vezani ariltriazoloni i njihova uporaba
IL275762B2 (en) History of PHENYL-SO2-NH-C(=O)-PHENYL-PIPERAZINE-CH2-1,2-CYCLOHEXANE-BICYCLO[1.1.1]PENTANE and spirit preparations containing them
JP2019514874A5 (cg-RX-API-DMAC7.html)
JOP20210001A1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
RU2007103815A (ru) Производное тиенопиразола, имеющее ингибирующую фосфодиэстеразу 7(pde 7) активность
OA12697A (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
FI4360713T3 (fi) Kinatsoliinijohdannaisia kasvaimia estävinä aineina
FI4019019T3 (fi) Rilutsolin, rilutsolin aihiolääkkeiden tai rilutsolin analogien käyttö immunoterapioiden kanssa syövän hoidossa
HRP20161428T1 (hr) Modulatori farmakokinetičkih svojstava lijekova
WO2010055304A3 (en) Oxazole or imidazole derivatives for use in the treatment of autoimmune disesases, in particular multiple sclerosis
JP2013532652A5 (cg-RX-API-DMAC7.html)
JP2016518434A5 (cg-RX-API-DMAC7.html)
WO2007146124A3 (en) Deuterated tadalafil derivatives
JP2019532092A5 (cg-RX-API-DMAC7.html)
RU2403253C2 (ru) Пуриновые производные для применения в качестве агонистов аденозинового рецептора а-2а
JP2019527724A5 (cg-RX-API-DMAC7.html)
CA2728098A1 (en) Pyrazole-containing tricyclic compounds as_antagonits of an ep1 receptor
JP2018535261A5 (cg-RX-API-DMAC7.html)
JP2018504411A5 (cg-RX-API-DMAC7.html)
JP2021505542A5 (cg-RX-API-DMAC7.html)
CA2581232A1 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
HRP20231092T1 (hr) Inhibitori arginaze i postupci njihove primjene
JP2006517932A5 (cg-RX-API-DMAC7.html)